Atlas Arteria Limited (OTCMKTS:MAQAF – Get Free Report) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 5,755,870 shares, an increase of 264.3% from the June 15th total of 1,579,770 shares. Based on an average trading volume of 2,955 shares, the short-interest ratio is currently 1,947.8 days.
Atlas Arteria Stock Performance
MAQAF remained flat at $3.55 during trading on Friday. Atlas Arteria has a 52 week low of $2.69 and a 52 week high of $3.70. The stock has a fifty day moving average of $3.45 and a 200 day moving average of $3.33.
Analysts Set New Price Targets
Separately, Royal Bank Of Canada downgraded Atlas Arteria to an “underperform” rating and set a $4.75 price target for the company. in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell” and an average target price of $4.75.
Atlas Arteria Company Profile
Atlas Arteria (OTCMKTS: MAQAF) is a global toll road owner and operator specializing in the development, management and long-term investment of transport infrastructure. The company partners with governments and institutional investors to acquire, manage and optimise concession-based road assets, generating stable revenue streams through user fees and toll collections. Atlas Arteria focuses on enhancing traffic flow and safety through targeted capital improvements and operational efficiencies across its portfolio.
The company’s primary assets span North America, Europe and Australia.
See Also
- Five stocks we like better than Atlas Arteria
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Atlas Arteria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Arteria and related companies with MarketBeat.com's FREE daily email newsletter.
